Interferon alpha-2b inhalation - BioSante Pharmaceuticals

Drug Profile

Interferon alpha-2b inhalation - BioSante Pharmaceuticals

Latest Information Update: 30 Jul 2013

Price : $50

At a glance

  • Originator BioSante Pharmaceuticals
  • Developer ANI Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 18 Jul 2013 BioSante Pharmaceuticals is now called ANI Pharmaceuticals
  • 18 Jul 2013 Discontinued - Clinical-Phase-Unknown for Hepatitis B in USA (Inhalation) prior to July 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top